Repeated cycles of peptide receptor radionuclide therapy (PRRT) - Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/ 177Lu-DOTA TATE therapy in patients with disseminated NET

Radiotherapy and Oncology

Volumn 102, Issue 1, 2012, Pages 45-50

  Pach, Dorota ^a   Sowa Staszczak, Anna ^a   Kunikowska, Jolanta ^b   Królicki, Leszek ^b   Trofimiuk, Małgorzata ^a   Stefańska, Agnieszka ^a   Tomaszuk, Monika ^a   Głowa, Bogusław ^a   Mikołajczak, Renata ^c   Pawlak, Dariusz ^c   Jabrocka Hybel, Agata ^a   Hubalewska Dydejczyk, Alicja B ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

Author keywords

Bone marrow toxicity; Neuroendocrine tumors; Peptide receptor radionuclide therapy (PRRT); Renal toxicity; Repeated cycles of PRRT

Indexed keywords

LUTETIUM 177; YTTRIUM 90;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER RADIOTHERAPY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; RADIATION DOSE; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; TUMOR VOLUME;

AGED; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; HUMANS; LUTETIUM; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES; RECEPTORS, PEPTIDE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR BURDEN; YTTRIUM RADIOISOTOPES;

EID: 84455199744     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.08.006     Document Type: Article

References (24)

1. M. Gabriel, U. Andergassen, and D. Putzer Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients Q J Nucl Med Mol Imaging 54 2010 92 99
2. E.H. Tan, and C.H. Tan Imaging of gastroenteropancreatic neuroendocrine tumors World J Clin Oncol 2 2011 28 43
3. M. Falconi, U. Plockinger, and D.J. Kwekkeboom Well-differentiated pancreatic nonfunctioning tumors/carcinoma Neuroendocrinology 84 2006 196 211
4. D.J. Kwekkeboom, J. Mueller-Brand, and G. Paganelli Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs J Nucl Med 46 2005 62S 66S
5. M. de Jong, W.A. Breeman, and R. Valkema Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs J Nucl Med 46 2005 13S 17S
6. I.M. Modlin, K. Oberg, and D.C. Chung Gastroenteropancreatic neuroendocrine tumors Lancet Oncol 9 2008 61 72
7. P. Therasse, S. Arbuck, and E. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
8. E. Eisenhauer, P. Therasse, and J. Bogaerts Et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
9. H. Choi, C. Charnsa ngavei, and S.C. Faria Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753 1759
10. R.L. Wahl, H. Jacene, and Y. Kasamon From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors J Nucl Med 50 2009 122S 150S
11. E.J. Rolleman, M. Melis, and R. Valkema Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues Eur J Nucl Med Mol Imaging 37 2010 1018 1031
12. R. Barone, F. Borson-Chazot, and R. Valkema Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship J Nucl Med 46 2005 99S 106S
13. M. Cybulla, S.M. Weiner, and A. Otte End-stage renal disease after treatment with 90Y-DOTATOC Eur J Nucl Med 28 2001 1552 1554
14. R. Valkema, S.A. Pauwels, and L.K. Kvols Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate J Nucl Med 46 2005 83S 91S
15. E.J. Rolleman, E.P. Krenning, and B.F. Bernard Long-term toxicity of [177Lu-DOTA0, Tyr3]octreotate in rats Eur J Nucl Med Mol Imaging 34 2007 219 227
16. S. Moll, V. Nickeleit, and J. Mueller-Brand A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy Am J Kidney Dis 37 2001 847 851
17. A. Otte, R. Herrmann, and A. Heppeler Yttrium-90 DOTATOC: first clinical results Eur J Nucl Med 26 1999 1439 1447
18. M. De Jong, E.J. Rolleman, and B.F. Bernard Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo J Nucl Med 37 1996 1388 1392
19. E.J. Rolleman, R. Valkema, and M. De Jong Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine Eur J Nucl Med Mol Imaging 30 2003 9 15
20. R. Barone, S. Pauwels, and J. De Camps Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues Nephrol Dial Transplant 19 2004 2275 2281
21. L. Bodei, M. Cremonesi, and S. Zoboli Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study Eur J Nucl Med Mol Imaging 30 2003 207 216
22. P.J. Hammond, A.F. Wade, and M.E. Gwilliam Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue Br J Cancer 67 1993 1437 1439
23. M. De Jong, E.J. Rolleman, and B.F. Bernard Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo J Nucl Med 37 1996 1388 1392
24. M. Behe, S. Koller, and M. Pusken Irradiation-induced upregulation of somatostatin and gastrin receptors in vitro and in vivo Eur J Nucl Med Mol Imaging 31 2004 S237 S238